Consultation record

Submissions accepted in part — page 11

Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.

Submissions

377 documents · page 11 of 13

Table 1. Submissions with this disposition, on this page.

Reference	Consultation	Respondent	Point raised
DRAFT-POORLY-RETAI/005	Draft standard CEI-MS-19: Purity determination for peptides not…	Dr Marisol Dunmore-Ekpo	Acceptance criteria are expressed in terms specific to one instrument family
DRAFT-PHOTOSTABILI/001	Draft standard CEI-MS-20: Photostability assessment of…	Dr Amara Quaresma	Nothing requires a laboratory to demonstrate ongoing performance
DRAFT-INCRETIN-CAR/010	Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…	Dr Jolanta Uttridge	Point estimates are given without an interval
DRAFT-INCRETIN-CAR/005	Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…	Dr Lorcan Zaleski-Mbeki	A surrogate outcome is used as the anchor without validation evidence
DRAFT-INCRETIN-CAR/012	Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…	Dr Eamon Immelmann	The choice of effect measure is not justified and changes the appearance of the result
DRAFT-INCRETIN-CAR/007	Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…	Dr Jacinta Steenkamp-Ferreira	Subgroup findings are reported that were not registered in the protocol
DRAFT-INCRETIN-CAR/004	Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…	Yusuf Whitmarsh-Obi	Studies not published in English were excluded without assessment
DRAFT-GASTROINTEST/006	Draft synthesis: Gastrointestinal adverse events with incretin…	Xenia Nyquist-Obiora industry	A sponsor trial meeting the eligibility criteria was excluded
DRAFT-GASTROINTEST/003	Draft synthesis: Gastrointestinal adverse events with incretin…	Dr Wilhelmina Erlingsson	References should carry a persistent identifier for every cited source
DRAFT-GASTROINTEST/002	Draft synthesis: Gastrointestinal adverse events with incretin…	Dr Rosalind Grünbaum-Sowande	Point estimates are given without an interval
DRAFT-GASTROINTEST/004	Draft synthesis: Gastrointestinal adverse events with incretin…	Dr Adaeze Dunmore-Ekpo	The review protocol is described but its registration record is not linked
DRAFT-ORAL-VS-INJE/014	Draft synthesis: Oral compared with injectable presentations of…	Dr Katarzyna Oppenheimer-Ade	The same concern is used to downgrade in two domains
DRAFT-ORAL-VS-INJE/013	Draft synthesis: Oral compared with injectable presentations of…	Dr Ivo Quintanilha	The document is unreadable without specialist training
DRAFT-ORAL-VS-INJE/007	Draft synthesis: Oral compared with injectable presentations of…	Dr Ottoline Fitzgerald-Nwosu	Two included studies do not meet the registered eligibility criteria
DRAFT-ORAL-VS-INJE/010	Draft synthesis: Oral compared with injectable presentations of…	Dr Georgiana Mountstephen	Subgroup findings are reported that were not registered in the protocol
DRAFT-ORAL-VS-INJE/015	Draft synthesis: Oral compared with injectable presentations of…	Dr Vittoria Ylönen	Patient-reported outcomes are collected by the trials and not reported by the review
DRAFT-ORAL-VS-INJE/009	Draft synthesis: Oral compared with injectable presentations of…	Dr Jolanta Uttridge	Statistical heterogeneity is treated as though it measured clinical heterogeneity
DRAFT-RENAL-OUTCOM/005	Draft synthesis: Kidney outcomes with incretin receptor agonists in…	Dr Torvald Kettlewell	Regulatory assessment documents were not searched
DRAFT-RENAL-OUTCOM/004	Draft synthesis: Kidney outcomes with incretin receptor agonists in…	Dr Lorcan Trelawney	The choice of effect measure is not justified and changes the appearance of the result
DRAFT-RENAL-OUTCOM/002	Draft synthesis: Kidney outcomes with incretin receptor agonists in…	Dr Yaa Kettlewell	Subgroup findings are reported that were not registered in the protocol
DRAFT-RENAL-OUTCOM/010	Draft synthesis: Kidney outcomes with incretin receptor agonists in…	Dr Ulysses Bellingham-Ojo industry	A sponsor trial meeting the eligibility criteria was excluded
DRAFT-RENAL-OUTCOM/011	Draft synthesis: Kidney outcomes with incretin receptor agonists in…	Radoslava Palmgren-Kofi	Point estimates are given without an interval
DRAFT-HFPEF-INCRET/003	Draft synthesis: Incretin receptor agonists in heart failure with…	Dr Kamila Ubertini	Two included studies do not meet the registered eligibility criteria
DRAFT-HFPEF-INCRET/002	Draft synthesis: Incretin receptor agonists in heart failure with…	Dr Ludmila Castellanos-Reid	Patient-reported outcomes are collected by the trials and not reported by the review
DRAFT-SLEEP-APNOEA/007	Draft synthesis: Weight-reducing agents for obstructive sleep apnoea	Dr Gaspard Wintringham	The document is unreadable without specialist training
DRAFT-SLEEP-APNOEA/012	Draft synthesis: Weight-reducing agents for obstructive sleep apnoea	Dr Vittoria Ylönen industry	A sponsor trial meeting the eligibility criteria was excluded
DRAFT-SLEEP-APNOEA/013	Draft synthesis: Weight-reducing agents for obstructive sleep apnoea	Dr Katarzyna Oppenheimer-Ade	Subgroup findings are reported that were not registered in the protocol
DRAFT-SLEEP-APNOEA/008	Draft synthesis: Weight-reducing agents for obstructive sleep apnoea	Dr Oisín Rautavaara	A surrogate outcome is used as the anchor without validation evidence
DRAFT-SLEEP-APNOEA/014	Draft synthesis: Weight-reducing agents for obstructive sleep apnoea	Dr Ivo Quintanilha	Regulatory assessment documents were not searched
DRAFT-SLEEP-APNOEA/011	Draft synthesis: Weight-reducing agents for obstructive sleep apnoea	Dr Mordecai Glendinning-Uche	The choice of effect measure is not justified and changes the appearance of the result

page 11 of 13